CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Healthcare & Pipeline Overview

CytomX Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing Probody therapeutics for cancer treatment. With a pipeline of antibody drug conjugates and strategic partnerships, the company aims to improve cancer therapy efficacy and safety, operating within the competitive oncology-focused biotechnology sector.

What Is the Investment Thesis for CTMX?

CytomX Therapeutics presents a compelling investment thesis centered on its innovative Probody technology and diverse clinical pipeline. The company's approach to developing conditionally activated antibody therapeutics offers the potential for safer and more effective cancer treatments. Key value drivers include the advancement of CX-2009 and CX-2029 through Phase II clinical trials, with potential data readouts expected in the next 12-18 months. Strategic collaborations with major pharmaceutical companies like Bristol-Myers Squibb and Amgen provide financial stability and validation of the Probody platform. However, the company's negative profit margin of -166.4% and high beta of 2.48 indicate significant financial risk. Successful clinical trial outcomes and continued partnership development are crucial for driving long-term value. The company's market capitalization of $611.82M reflects both the potential and the risks associated with its clinical-stage development.

Based on FMP financials and quantitative analysis

CTMX Key Highlights

• Market capitalization of $611.82M, reflecting investor valuation of CytomX's pipeline and technology.
• Gross margin of 69.7%, indicating strong potential profitability upon commercialization of products.
• Profit margin of -166.4%, highlighting the significant ongoing investment in research and development.
• Strategic collaborations with major pharmaceutical companies, including Bristol-Myers Squibb and Amgen, validating the Probody technology.
• Multiple clinical-stage programs, including CX-2009 and CX-2029 in Phase II trials, demonstrating progress towards potential market approval.

Who Are CTMX's Competitors?

CTMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTMX's Key Strengths?

• Innovative Probody technology platform.
• Strategic collaborations with major pharmaceutical companies.
• Clinical-stage pipeline of product candidates.
• Strong intellectual property portfolio.

What Are CTMX's Weaknesses?

• High operating expenses due to research and development costs.
• Dependence on clinical trial outcomes for product approval.
• Negative profit margin.
• Limited commercialization experience.

What Could Drive CTMX Stock Higher?

• Data readouts from Phase II clinical trials of CX-2009 in breast cancer (expected in the next 12-18 months).
• Data readouts from Phase II clinical trials of CX-2029 in squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma (expected in the next 18-24 months).
• Advancement of BMS-986249 and BMS-986288 through Phase I/II and Phase I clinical trials, respectively.
• Potential for new strategic collaborations with pharmaceutical companies to develop Probody therapeutics.

What Are the Key Risks for CTMX?

• Negative return on equity (-36.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for product candidates.
• Regulatory delays or rejection of product candidates.
• Competition from other biotechnology and pharmaceutical companies.
• Dependence on strategic collaborations for funding and development.
• Patent challenges to the Probody technology.

What Are the Growth Opportunities for CTMX?

• Expansion of Clinical Pipeline: CytomX has the opportunity to expand its clinical pipeline by advancing its early-stage programs, such as CX-2043 and CX-904, into clinical trials. The market for novel cancer therapies is substantial, with a global oncology market projected to reach $286 billion by 2028. Successful development and commercialization of these programs could significantly increase CytomX's revenue and market share. The timeline for this growth opportunity is dependent on clinical trial progress, with potential for new programs entering Phase I trials within the next 2-3 years.
• Strategic Collaborations: CytomX can leverage its Probody technology platform to establish new strategic collaborations with pharmaceutical companies. The demand for innovative cancer therapies is driving increased investment in partnerships and licensing agreements. By securing additional collaborations, CytomX can gain access to funding, expertise, and resources to accelerate the development and commercialization of its product candidates. This growth opportunity is ongoing, with potential for new collaborations to be announced in the next 12-18 months.
• Advancement of CX-2009: The advancement of CX-2009, an antibody-drug conjugate (ADC) targeting CD166, through Phase II clinical trials for breast cancer represents a significant growth opportunity. Breast cancer is one of the most prevalent cancers worldwide, with a global market size estimated at $24.9 billion in 2023. Positive clinical trial results and subsequent regulatory approval could lead to substantial revenue generation for CytomX. Data readouts from the Phase II trials are expected in the next 12-18 months, which will be a critical milestone for this growth opportunity.
• Development of CX-2029: The development of CX-2029, targeting squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma, represents a broad growth opportunity. These cancers have significant unmet medical needs, and successful development of CX-2029 could address a substantial market. Phase II clinical trial results are expected in the next 18-24 months, which will be a key factor in determining the potential of this growth opportunity.
• Expansion into New Therapeutic Areas: CytomX has the potential to expand its Probody technology into new therapeutic areas beyond oncology. The platform's ability to create conditionally activated therapeutics could be applied to other diseases with localized pathology, such as autoimmune disorders or inflammatory conditions. This expansion could diversify CytomX's pipeline and revenue streams, reducing its reliance on the oncology market. The timeline for this growth opportunity is longer-term, with potential for new programs in other therapeutic areas to emerge in the next 3-5 years.

What Opportunities Does CTMX Have?

• Expansion of clinical pipeline into new therapeutic areas.
• Establishment of new strategic collaborations.
• Advancement of product candidates through clinical trials.
• Potential for regulatory approval and commercialization of Probody therapeutics.

What Threats Does CTMX Face?

• Competition from other biotechnology and pharmaceutical companies.
• Failure of clinical trials.
• Regulatory hurdles and delays.
• Patent challenges.

What Are CTMX's Competitive Advantages?

• Proprietary Probody technology platform that enables the development of conditionally activated antibody therapeutics.
• Strong intellectual property portfolio protecting the Probody technology and product candidates.
• Established strategic collaborations with major pharmaceutical companies, providing access to funding and expertise.
• Clinical-stage pipeline of product candidates with potential for significant market opportunity.

What Does CTMX Do?

Founded in 2008 and headquartered in South San Francisco, California, CytomX Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The company's core technology is its Probody platform, which is designed to create conditionally activated antibody therapeutics. These Probodies are engineered to remain inactive until they reach the tumor microenvironment, reducing off-target effects and improving the therapeutic window. CytomX's pipeline includes several clinical-stage product candidates. CX-2009, an antibody-drug conjugate (ADC) targeting CD166, is in Phase II clinical trials for breast cancer. CX-2029 is also in Phase II trials, targeting squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is developing BMS-986249, a CTLA-4 Probody therapeutic, and BMS-986288, an anti-CTLA-4 Probody drug, both in Phase I/II and Phase I clinical trials, respectively, for various solid tumors. The company also has early-stage programs like CX-2043 and CX-904. CytomX has established strategic collaborations with major pharmaceutical companies, including AbbVie, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer, and Astellas Pharma, to advance its Probody therapeutics. These collaborations provide financial support and validation for CytomX's technology platform.

What Products and Services Does CTMX Offer?

• Develop antibody therapeutics based on the Probody technology platform.
• Create conditionally activated antibody therapeutics for cancer treatment.
• Design Probodies that remain inactive until they reach the tumor microenvironment.
• Conduct clinical trials to evaluate the safety and efficacy of Probody therapeutics.
• Collaborate with pharmaceutical companies to advance the development of Probody therapeutics.
• Target various cancers, including breast cancer, lung cancer, and head and neck cancer.
• Develop antibody-drug conjugates (ADCs) for targeted cancer therapy.

How Does CTMX Make Money?

• Develop and out-license Probody therapeutics to pharmaceutical partners.
• Generate revenue through upfront payments, milestone payments, and royalties from collaborations.
• Retain rights to certain programs for independent development and commercialization.
• Focus on early-stage research and clinical development of Probody therapeutics.

What Industry Does CTMX Operate In?

CytomX Therapeutics operates within the competitive and rapidly evolving biotechnology industry, specifically focusing on oncology. The market for cancer therapeutics is substantial, driven by the increasing prevalence of cancer and advancements in personalized medicine. The industry is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk associated with clinical trials. CytomX's Probody technology aims to differentiate itself by offering improved safety and efficacy compared to traditional antibody therapies. Competitors like ERAS: Erasca, Inc. are also developing novel cancer treatments, creating a dynamic landscape of innovation and competition.

Who Are CTMX's Key Customers?

• Pharmaceutical companies that license CytomX's Probody technology.
• Patients who may benefit from CytomX's cancer therapies.
• Healthcare providers who prescribe CytomX's therapies.
• Research institutions involved in clinical trials of CytomX's products.

FY2026 estForward Outlook

Wall Street analysts project CytomX Therapeutics, Inc. revenue of about $32.1M for fiscal 2026, with EPS near $-0.42. The estimate reflects 5 contributing analysts.

F-Score 1/9Financial Health

CytomX Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.13 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -37%Key Financial Metrics

Return on equity for CytomX Therapeutics, Inc. stands at -36.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.6%, the inverse of the P/E and a quick read on earnings relative to price.

CytomX Therapeutics, Inc. (CTMX) Valuation Context

Valued at $611.82M, CTMX is classified as a small-cap stock. Relative to its peer group, CTMX's quantitative score of 22/100 is below the peer average of 76/100.

CTMX Revenue & Earnings Trend

In Q1 2026, CTMX generated $10.3M in top-line revenue, marking a sequential increase of 1447.2%. The company recorded a net loss of $18.2M, with diluted EPS of $-0.10. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CTMX averaged $-0.09 in diluted EPS.

Company Profile

CytomX Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Sean A. McCarthy. CTMX has traded publicly since 2015.

CTMX Financials

CTMX Latest News

CTMX Analyst Consensus

CTMX MoonshotScore

Latest CytomX Therapeutics, Inc. Analysis

Common Questions About CTMX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources